149 related articles for article (PubMed ID: 32916277)
1. Nelfinavir inhibits human DDI2 and potentiates cytotoxicity of proteasome inhibitors.
Gu Y; Wang X; Wang Y; Wang Y; Li J; Yu FX
Cell Signal; 2020 Nov; 75():109775. PubMed ID: 32916277
[TBL] [Abstract][Full Text] [Related]
2. Disabling the Protease DDI2 Attenuates the Transcriptional Activity of NRF1 and Potentiates Proteasome Inhibitor Cytotoxicity.
Northrop A; Vangala JR; Feygin A; Radhakrishnan SK
Int J Mol Sci; 2020 Jan; 21(1):. PubMed ID: 31947743
[TBL] [Abstract][Full Text] [Related]
3. Multiple myeloma cells depend on the DDI2/NRF1-mediated proteasome stress response for survival.
Chen T; Ho M; Briere J; Moscvin M; Czarnecki PG; Anderson KC; Blackwell TK; Bianchi G
Blood Adv; 2022 Jan; 6(2):429-440. PubMed ID: 34649278
[TBL] [Abstract][Full Text] [Related]
4. The aspartyl protease DDI2 drives adaptation to proteasome inhibition in multiple myeloma.
Op M; Ribeiro ST; Chavarria C; De Gassart A; Zaffalon L; Martinon F
Cell Death Dis; 2022 May; 13(5):475. PubMed ID: 35589686
[TBL] [Abstract][Full Text] [Related]
5. DDI2 Is a Ubiquitin-Directed Endoprotease Responsible for Cleavage of Transcription Factor NRF1.
Dirac-Svejstrup AB; Walker J; Faull P; Encheva V; Akimov V; Puglia M; Perkins D; Kümper S; Hunjan SS; Blagoev B; Snijders AP; Powell DJ; Svejstrup JQ
Mol Cell; 2020 Jul; 79(2):332-341.e7. PubMed ID: 32521225
[TBL] [Abstract][Full Text] [Related]
6. Nelfinavir Inhibits the TCF11/Nrf1-Mediated Proteasome Recovery Pathway in Multiple Myeloma.
Fassmannová D; Sedlák F; Sedláček J; Špička I; Grantz Šašková K
Cancers (Basel); 2020 Apr; 12(5):. PubMed ID: 32344880
[TBL] [Abstract][Full Text] [Related]
7. Mammalian Ddi2 is a shuttling factor containing a retroviral protease domain that influences binding of ubiquitylated proteins and proteasomal degradation.
Collins GA; Sha Z; Kuo CL; Erbil B; Goldberg AL
J Biol Chem; 2022 May; 298(5):101875. PubMed ID: 35358511
[TBL] [Abstract][Full Text] [Related]
8. Carfilzomib resistance due to ABCB1/MDR1 overexpression is overcome by nelfinavir and lopinavir in multiple myeloma.
Besse A; Stolze SC; Rasche L; Weinhold N; Morgan GJ; Kraus M; Bader J; Overkleeft HS; Besse L; Driessen C
Leukemia; 2018 Feb; 32(2):391-401. PubMed ID: 28676669
[TBL] [Abstract][Full Text] [Related]
9. The aspartyl protease DDI2 activates Nrf1 to compensate for proteasome dysfunction.
Koizumi S; Irie T; Hirayama S; Sakurai Y; Yashiroda H; Naguro I; Ichijo H; Hamazaki J; Murata S
Elife; 2016 Aug; 5():. PubMed ID: 27528193
[TBL] [Abstract][Full Text] [Related]
10. The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo.
Bono C; Karlin L; Harel S; Mouly E; Labaume S; Galicier L; Apcher S; Sauvageon H; Fermand JP; Bories JC; Arnulf B
Haematologica; 2012 Jul; 97(7):1101-9. PubMed ID: 22271897
[TBL] [Abstract][Full Text] [Related]
11. Antitumorigenic action of nelfinavir: Effects on multiple myeloma and hematologic malignancies (Review).
Allegra A; Innao V; Allegra AG; Pulvirenti N; Pugliese M; Musolino C
Oncol Rep; 2020 Jun; 43(6):1729-1736. PubMed ID: 32236596
[TBL] [Abstract][Full Text] [Related]
12. Treatment with HIV-Protease Inhibitor Nelfinavir Identifies Membrane Lipid Composition and Fluidity as a Therapeutic Target in Advanced Multiple Myeloma.
Besse L; Besse A; Stolze SC; Sobh A; Zaal EA; van der Ham AJ; Ruiz M; Phuyal S; Büchler L; Sathianathan M; Florea BI; Borén J; Ståhlman M; Huber J; Bolomsky A; Ludwig H; Hannich JT; Loguinov A; Everts B; Berkers CR; Pilon M; Farhan H; Vulpe CD; Overkleeft HS; Driessen C
Cancer Res; 2021 Sep; 81(17):4581-4593. PubMed ID: 34158378
[TBL] [Abstract][Full Text] [Related]
13. Ritonavir, nelfinavir, saquinavir and lopinavir induce proteotoxic stress in acute myeloid leukemia cells and sensitize them for proteasome inhibitor treatment at low micromolar drug concentrations.
Kraus M; Müller-Ide H; Rückrich T; Bader J; Overkleeft H; Driessen C
Leuk Res; 2014 Mar; 38(3):383-92. PubMed ID: 24418752
[TBL] [Abstract][Full Text] [Related]
14. Improving the efficacy of proteasome inhibitors in the treatment of renal cell carcinoma by combination with the human immunodeficiency virus (HIV)-protease inhibitors lopinavir or nelfinavir.
Abt D; Besse A; Sedlarikova L; Kraus M; Bader J; Silzle T; Vodinska M; Slaby O; Schmid HP; Engeler DS; Driessen C; Besse L
BJU Int; 2018 Apr; 121(4):600-609. PubMed ID: 29161753
[TBL] [Abstract][Full Text] [Related]
15. The cytotoxic activity of carfilzomib together with nelfinavir is superior to the bortezomib/nelfinavir combination in non-small cell lung carcinoma.
Besse L; Kraus M; Besse A; Driessen C; Tarantino I
Sci Rep; 2023 Mar; 13(1):4411. PubMed ID: 36932175
[TBL] [Abstract][Full Text] [Related]
16. The HIV protease inhibitors nelfinavir and saquinavir, but not a variety of HIV reverse transcriptase inhibitors, adversely affect human proteasome function.
Piccinini M; Rinaudo MT; Anselmino A; Buccinnà B; Ramondetti C; Dematteis A; Ricotti E; Palmisano L; Mostert M; Tovo PA
Antivir Ther; 2005; 10(2):215-23. PubMed ID: 15865215
[TBL] [Abstract][Full Text] [Related]
17. The HIV protease inhibitor nelfinavir down-regulates RET signaling and induces apoptosis in medullary thyroid cancer cells.
Kushchayeva Y; Jensen K; Recupero A; Costello J; Patel A; Klubo-Gwiezdzinska J; Boyle L; Burman K; Vasko V
J Clin Endocrinol Metab; 2014 May; 99(5):E734-45. PubMed ID: 24483157
[TBL] [Abstract][Full Text] [Related]
18. Could the FDA-approved anti-HIV PR inhibitors be promising anticancer agents? An answer from enhanced docking approach and molecular dynamics analyses.
Arodola OA; Soliman ME
Drug Des Devel Ther; 2015; 9():6055-65. PubMed ID: 26622167
[TBL] [Abstract][Full Text] [Related]
19. HIV-1 protease inhibitors nelfinavir and atazanavir induce malignant glioma death by triggering endoplasmic reticulum stress.
Pyrko P; Kardosh A; Wang W; Xiong W; Schönthal AH; Chen TC
Cancer Res; 2007 Nov; 67(22):10920-8. PubMed ID: 18006837
[TBL] [Abstract][Full Text] [Related]
20. In-silico identification of novel DDI2 inhibitor in glioblastoma
Roy PK; Majumder R; Mandal M
J Biomol Struct Dyn; 2024 Mar; 42(5):2270-2281. PubMed ID: 37139547
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
